Upadacitinib 15 MG

DRUG6 trials

Sponsors

Modern Biosciences Ltd, Jilin University, Northwestern University, University Hospital, Toulouse, Assiut University

Conditions

Behcet SyndromeEyelid DermatitisInterstitial Lung Disease Due to Systemic Disease (Disorder)PharmacokineticsRhumatoid ArthisisVitiligo

Early Phase 1

Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis

Not yet recruitingNCT06684522

Northwestern UniversityEyelid Dermatitis

Start: 2024-12-31End: 2026-03-31Target: 10Updated: 2024-11-12

Phase 1

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

RecruitingNCT06379958

Modern Biosciences LtdPharmacokinetics

Start: 2024-04-08End: 2024-09-30Target: 48Updated: 2024-08-09

Phase 2

Upadacitinib for Refractory Behcet's Syndrome

CompletedNCT07080346

Liu TianBehcet Syndrome

Start: 2024-01-25End: 2025-07-08Updated: 2025-12-02

Phase 3

Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

CompletedNCT06758947

Assiut UniversityInterstitial Lung Disease Due to Systemic Disease (Disorder)

Start: 2023-01-15End: 2024-11-15Updated: 2025-01-06

Phase 4

JAK Inhibitor Dose TAPering Strategy Study

Not yet recruitingNCT06687551

University Hospital, ToulouseRhumatoid Arthisis

Start: 2025-01-01End: 2029-04-01Target: 308Updated: 2024-11-13

Unknown Phase

Efficacy of Upadacitinib After NECS in Vitiligo

RecruitingNCT06454461

Jilin UniversityVitiligo

Start: 2024-12-04End: 2029-06-01Target: 60Updated: 2024-12-27